{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:19:38Z","timestamp":1785205178016,"version":"3.55.0"},"reference-count":25,"publisher":"Akademiai Kiado Zrt.","issue":"25","content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,6,25]]},"abstract":"<jats:p>A velesz\u00fcletett komplementdefektusok vil\u00e1gszerte ritk\u00e1n fordulnak el\u0151, a primer\n                    immunhi\u00e1nyok 1\u201310%-\u00e1t teszik ki. A szerzett komplementdefektusok gyakoribbak, \u00e9s\n                    a komplementg\u00e1tl\u00f3 kezel\u00e9sek egyre elterjedtebb alkalmaz\u00e1s\u00e1val a szerzett\n                    komplementhi\u00e1nyos betegek incidenci\u00e1ja n\u0151. A ter\u00e1pia okozta\n                    komplementdeficientia a genetikailag meghat\u00e1rozott form\u00e1khoz hasonl\u00f3an d\u00f6nt\u0151en\n                    tokos bakt\u00e9riumok \u00e1ltal okozott, visszat\u00e9r\u0151en jelentkez\u0151, \u00e9letvesz\u00e9lyes\n                    fert\u0151z\u00e9sekre hajlamos\u00edt (sepsis, meningitis). A leggyakoribb k\u00f3rokoz\u00f3k a\n                        <jats:italic>Neisseria meningitidis,<\/jats:italic> a <jats:italic>Streptococcus pneumoniae\n                        \u00e9s a Haemophilus influenzae.<\/jats:italic> Haz\u00e1nkban C5- \u00e9s C3-komplement-g\u00e1tl\u00f3\n                    gy\u00f3gyszerek \u00e9rhet\u0151k el a klinikai gyakorlatban, melyek els\u0151dlegesen paroxysmalis\n                    nocturnalis haemoglobinuria, myasthenia gravis, neuromyelitis optica \u00e9s at\u00edpusos\n                    haemolyticus uraemi\u00e1s szindr\u00f3m\u00e1s betegek kezel\u00e9s\u00e9re indik\u00e1ltak. A fenti\n                    kezel\u00e9sben r\u00e9szes\u00fcl\u0151 betegek k\u00f6r\u00e9ben kiemelt jelent\u0151s\u00e9g\u0171 \u00e9s a kezel\u00e9snek\n                    elengedhetetlen felt\u00e9tele a s\u00falyos, potenci\u00e1lisan \u00e9letet vesz\u00e9lyeztet\u0151, gyors\n                    progresszi\u00f3j\u00fa bakteri\u00e1lis fert\u0151z\u00e9sek megel\u0151z\u00e9se. Ennek ellen\u00e9re az infekci\u00f3s\n                    kock\u00e1zatot cs\u00f6kkent\u0151 hazai aj\u00e1nl\u00e1s nem l\u00e9tezik, a megel\u0151z\u00e9si strat\u00e9gia nem\n                    standardiz\u00e1lt, gyakran hi\u00e1nyos, ami az \u00e9rintett betegeket s\u00falyosan\n                    vesz\u00e9lyezteti. K\u00f6zlem\u00e9ny\u00fcnk c\u00e9lja a nemzetk\u00f6zi gyakorlat \u00e9s klinikai \u00fatmutat\u00f3k\n                    \u00e1ttekint\u00e9s\u00e9vel a komplementhi\u00e1nyos betegekn\u00e9l alkalmazhat\u00f3 szakmai javaslat\n                    megfogalmaz\u00e1sa a bakteri\u00e1lis fert\u0151z\u00e9sek prevenci\u00f3j\u00e1ra vonatkoz\u00f3an, mely egy\n                    k\u00e9s\u0151bbi hazai ir\u00e1nyelv alapj\u00e1ul szolg\u00e1lhat. Orv Hetil. 2023; 164(25):\n                    971\u2013980.<\/jats:p>","DOI":"10.1556\/650.2023.32798","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T14:05:05Z","timestamp":1687788305000},"page":"971-980","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":2,"title":["Infekci\u00f3k kock\u00e1zat\u00e1nak cs\u00f6kkent\u00e9se velesz\u00fcletett \u00e9s szerzett komplementdefektusokban."],"prefix":"10.1556","volume":"164","author":[{"given":"\u00c9va","family":"Kar\u00e1szi","sequence":"first","affiliation":[{"name":"Budapest F\u0151v\u00e1ros XXII. ker\u00fclet, Budafok-T\u00e9t\u00e9ny \u00d6nkorm\u00e1nyzat, Budafoki Gyermekrendel\u0151 Budapest, K\u00e1ldor A. u. 5\u20139., 1221 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"Onoz\u00f3","sequence":"additional","affiliation":[{"name":"Borsod-Aba\u00faj-Zempl\u00e9n Megyei K\u00f3rh\u00e1z \u00e9s Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z, Velkey L\u00e1szl\u00f3 Gyermekeg\u00e9szs\u00e9g\u00fcgyi K\u00f6zpont Miskolc Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kulcs\u00e1r","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z \u2013 Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet, Szent L\u00e1szl\u00f3 K\u00f3rh\u00e1z Telephely, V\u00e9d\u0151olt\u00e1si Tan\u00e1csad\u00f3 Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Szl\u00e1vik","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z \u2013 Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet, Szent L\u00e1szl\u00f3 K\u00f3rh\u00e1z Telephely, Infektol\u00f3gia Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Goda","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z \u2013 Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet, Szent L\u00e1szl\u00f3 K\u00f3rh\u00e1z Telephely, Gyermekhematol\u00f3giai \u00e9s \u0150ssejt-transzplant\u00e1ci\u00f3s Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Kriv\u00e1n","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z \u2013 Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet, Szent L\u00e1szl\u00f3 K\u00f3rh\u00e1z Telephely, Gyermekhematol\u00f3giai \u00e9s \u0150ssejt-transzplant\u00e1ci\u00f3s Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Kutat\u00f3laborat\u00f3riuma Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botond","family":"Lakatos","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z \u2013 Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet, Szent L\u00e1szl\u00f3 K\u00f3rh\u00e1z Telephely, Infektol\u00f3gia Oszt\u00e1ly Budapest Magyarorsz\u00e1g"},{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika, Infektol\u00f3giai Tansz\u00e9ki Csoport Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1 Medscape. Complement deficiencies: background. Available from: https:\/\/emedicine.medscape.com\/article\/135478-overview#a4 [accessed: January 22, 2023]."},{"key":"ref1","unstructured":"2 UpToDate. Liszewski NK, Atkinson JP. Inherited disorders of the complement system. Available from: https:\/\/www.uptodate.com\/contents\/inherited-disorders-of-the-complement-system [accessed: January 22, 2023]."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"3 Tangye","year":"2022","unstructured":"3 Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022; 42: 1473-1507.","journal-title":"J Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar M","year":"2017","unstructured":"4 Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood 2017; 130: 891-899.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"20406207221114673","DOI":"10.1177\/20406207221114673","article-title":"Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria","volume":"13","author":"5 Wong","year":"2022","unstructured":"5 Wong RS. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2022; 13: 20406207221114673.","journal-title":"Ther Adv Hematol"},{"key":"ref5","unstructured":"6 European Medicines Agency. Soliris. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/soliris [accessed: January 22, 2023]."},{"key":"ref6","unstructured":"7 European Medicines Agency. Ultomiris, INN-ravulizumab. [Ultomiris. Alkalmaz\u00e1si el\u0151\u00edr\u00e1s.] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_hu.pdf [accessed: January 22, 2023]. [Hungarian]"},{"key":"ref7","unstructured":"8 European Medicines Agency. Aspaveli. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aspaveli [accessed: January 22, 2023]."},{"key":"ref8","unstructured":"9 Empaveli. Available from: https:\/\/empaveli.com\/possible-side-effects [accessed: January 22, 2023]."},{"key":"ref9","unstructured":"10 Biopharma PEG. Complement inhibitors as therapeutic agents. Available from: https:\/\/www.biochempeg.com\/article\/281.html [accessed: February 2, 2023]."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bbmt.2018.01.009","article-title":"Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation","volume":"24","author":"11 Horv\u00e1th","year":"2018","unstructured":"11 Horv\u00e1th O, K\u00e1llay K, Csuka D, et al. Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation. Biol Blood Marrow Transplant. 2018; 24: 989-996.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cei.13368","article-title":"Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency","volume":"198","author":"12 Van den Broek","year":"2019","unstructured":"12 Van den Broek B, van Els CA, Kuipers B, et al. Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency. Clin Exp Immunol. 2019; 198: 381-389.","journal-title":"Clin Exp Immunol"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13 Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27(Suppl 2): B112-B116.","DOI":"10.1016\/j.vaccine.2009.04.065"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14 Martin\u00f3n-Torres F, Bernatowska E, Shcherbina A, et al. Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function. Erratum: Pediatrics 2018; 142: e20174250. Pediatrics 2019; 143: e20183836.","DOI":"10.1542\/peds.2018-3836"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"69","author":"15 Mbaeyi","year":"2020","unstructured":"15 Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep. 2020; 69: 1-41.","journal-title":"MMWR Recomm Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"16 McNamara","year":"2017","unstructured":"16 McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Weekly 2017; 66: 734-737.","journal-title":"MMWR Weekly"},{"key":"ref16","unstructured":"17 National Renal Complement Therapeutics Centre. Guidelines for the prevention of meningococcal disease in adult patients recieving eculizumab or ravulizumab, or preapproved to receive eculizumab at point of renal transplantation. Available from: https:\/\/www.atypicalhus.co.uk\/wp-content\/uploads\/2022\/12\/Guidelines-for-the-prevention-of-meningococcal-disease-in-adult-patients-receiving-eculizumab-or-ravulizumab-FINAL-WEBSITE.pdf [accessed: February 2, 2023]."},{"key":"ref17","unstructured":"18 National Renal Complement Therapeutics Centre. Vaccination guideline for 18 years and under on eculizumab or ravulizumab. Available from: https:\/\/www.atypicalhus.co.uk\/wp-content\/uploads\/2022\/12\/Vaccination-guideline-for-18-years-and-under-on-eculizumab-or-ravulizumab-FINAL-WEBSITE.pdf [accessed: February 2, 2023]."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19 Ministry of Human Resources, State Secretariat for Healthcare, College of Health Care Professionals. Protocol for management of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). [Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma Eg\u00e9szs\u00e9g\u00fcgy\u00e9rt Felel\u0151s \u00c1llamtitk\u00e1rs\u00e1g, Eg\u00e9szs\u00e9g\u00fcgyi Szakmai Koll\u00e9gium. Eg\u00e9szs\u00e9g\u00fcgyi szakmai ir\u00e1nyelv - A thromboticus thrombocytopeni\u00e1s purpura (TTP) \u00e9s a haemolyticus uraemi\u00e1s szindr\u00f3ma (HUS) kezel\u00e9s\u00e9r\u0151l.] Orv Hetil. 2017; 158(Suppl 2): 1-44. [Hungarian]","DOI":"10.1556\/650.2017.30808"},{"key":"ref19","unstructured":"20 National Public Health Center. Protocol for vaccinations in 2023. [A Nemzeti N\u00e9peg\u00e9szs\u00e9g\u00fcgyi K\u00f6zpont m\u00f3dszertani levele a 2023. \u00e9vi v\u00e9d\u0151olt\u00e1sokr\u00f3l.] Available from: https:\/\/www.antsz.hu\/data\/cms107585\/VML_2023_NNK.pdf [accessed: March 31, 2023]. [Hungarian]"},{"key":"ref20","unstructured":"21 Centers for Disease Control and Prevention. Managing the risk of meningococcal disease among patients who receive complement inhibitor therapy. Available from: https:\/\/www.cdc.gov\/meningococcal\/clinical\/eculizumab.html [accessed: February 2, 2023]."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jinf.2019.11.015","article-title":"Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease","volume":"80","author":"22 Crew","year":"2020","unstructured":"22 Crew PE, McNamara L, Waldron PE, et al. Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease. J Infect. 2020; 80: 350-371.","journal-title":"J Infect"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23 Bozio CH, Isenhour C, McNamara LA. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS ONE 2020; 15: e0241989.","DOI":"10.1371\/journal.pone.0241989"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/ajh.25642","article-title":"Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders","volume":"94","author":"24 Malpica","year":"2019","unstructured":"24 Malpica L, van Duin D, Moll S. Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders. Am J Hematol. 2019; 94: 1396-1412.","journal-title":"Am J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12879-019-4752-2","article-title":"A study protocol of a controlled trial","volume":"20","author":"25 Bayrhuber","year":"2020","unstructured":"25 Bayrhuber M, Anka N, Camp J, Glattacker M, et al. Prevention of post-splenectomy sepsis in patients with asplenia. A study protocol of a controlled trial. BMC Infect Dis. 2020; 20: 41.","journal-title":"BMC Infect Dis"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/25\/article-p971.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/25\/article-p971.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/25\/article-p971.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T08:06:34Z","timestamp":1697702794000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/25\/article-p971.xml"}},"subtitle":["Irodalmi \u00e1ttekint\u00e9s \u00e9s javaslat hazai\n                    gyakorlatra"],"short-title":[],"issued":{"date-parts":[[2023,6,25]]},"references-count":25,"journal-issue":{"issue":"25"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32798","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,25]]}}}